Clinical Trial Update: Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 open-label, long-term study evaluating the safety and efficacy of subcutaneous amlitelimab in adolescents and adults with moderate-to-severe atopic derm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Dermatitis Atopic | Phase 2 | Status: ACTIVE_NOT_RECRUITING